CD86 and neoplasm: They expanded memory Vδ1 subpopulation using engineered APCs expressing CD86, 4-1BBL, CD40L and the CMV-antigen-pp65, obtaining polyclonal γδ T cells expressing activation and memory markers, with potent anti-tumor activity in vitro and in vivo with no sign of alloreactivity.